Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.75 |
| ▸ | JAK2 | O60674 | 2/20 | 0.71 |
| ▸ | JAK1 | P23458 | 2/20 | 0.71 |
| ▸ | JAK3 | P52333 | 2/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | TYK2 | P29597 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.63 |
| ▸ | ITK | Q08881 | 1/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.63 |
| ▸ | STK4 | Q13043 | 1/20 | 0.63 |
| ▸ | STK3 | Q13188 | 1/20 | 0.63 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.63 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241952 | 0.92 | SYK (0.79) | SYKJAK2JAK1JAK3CHEK1 | |
| SCHEMBL10241914 | 0.90 | SYK (0.79) | SYKJAK2JAK1JAK3CHEK1 | |
| SCHEMBL10241925 | 0.89 | SYK (0.84) | SYK | |
| SCHEMBL10242659 | 0.88 | SYK (0.77) | SYKJAK2JAK1JAK3CHEK1 | |
| SCHEMBL763457 | 0.88 | SYK (0.77) | SYKJAK2JAK1JAK3CHEK1 | |
| SCHEMBL736836 | 0.86 | SYK (1.00) | SYK | |
| SCHEMBL736835 | 0.86 | SYK (1.00) | SYK | |
| SCHEMBL736848 | 0.86 | SYK (1.00) | SYK | |
| SCHEMBL737037 | 0.85 | SYK (1.00) | SYK | |
| SCHEMBL737038 | 0.85 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321283-B1 | 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885JAK2 4/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.